Loading
OmniScience
OmniScience makes Vivo, an agentic AI layer that sits above EDC, CTMS, lab, safety and imaging systems so clinical trial teams can ask source-backed questions, monitor risk and act on it. Its customers are biopharma sponsors and clinical teams. For example, it partnered with INmune Bio on a Phase 2 Alzheimer's trial in 2024 and with LabConnect in 2025 on lab-data insights. It began in 2017 as Mercury Data Science, a data science consultancy spun out of Houston's Mercury Fund, and rebranded as OmniScience in January 2024. It is privately held with roughly 30–40 employees. PitchBook records a seed round in January 2025 and a later-stage VC round in December 2025, with amounts undisclosed. It is also in the NVIDIA Inception, Google for AI Startups and JLABS programs.
Funding
Every round, secondary, debt facility or acquisition involving OmniScience that Lounge tracks, newest first.
No rounds recorded yet.
Paid members see the full deals desk — every AI round and exit, filterable by type, sector and country, with investors and reported ARR, plus CSV exports. Developer membership is $9/mo.
See plans →Log inKey numbers
—
0
—
—